Implementing Low-Barrier HCV Treatment in a Jail Setting

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 11, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

August 31, 2027

Conditions
HEPATITIS C (HCV)IncarcerationInjection Drug UseImplementation Science
Interventions
DRUG

Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]

Individuals will receive a full course (i.e., 84 tablets) of Sofosbuvir / Velpatasvir 400/100mg tablets.

OTHER

Community Health Worker

Participants will receive support from a Community Health Worker which may include assistance with basic needs (transportation, housing, employment, vital documents, insurance re-activation) as well as medication adherence, patient navigation, and peer recovery support.

Trial Locations (1)

02920

RECRUITING

Rhode Island Department of Corrections, Cranston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Lifespan

OTHER

NCT06953479 - Implementing Low-Barrier HCV Treatment in a Jail Setting | Biotech Hunter | Biotech Hunter